Most pharma companies say they are. Very few have actually checked.
Regulatory updates, new markets, system upgrades, partner changes – none of these test a single tool. They test the entire L1–L5 serialization setup.
This checklist helps you assess whether your current architecture can absorb change without disrupting operations.
Serialization Readiness Checklist 2026 (L1–L5)
This is not educational content. It’s a diagnostic one. Most serialization issues don’t appear during implementation, but later, when operations are under pressure.
Teams often discover too late that:
- compliance works on paper
- reporting is fragmented
- manual work increases with every change
This checklist is designed to surface structural risks early, before they turn into delays, rework, or operational disruption.
What the Checklist Cover (L1–L5)
A practical self-check across the full serialization ecosystem:
Governance & ownership
- Is accountability clear across IT, QA, and Operations?
Line & site stability (L1–L2)
- Are exceptions and rework controlled — or handled manually?
Enterprise architecture (L3–L5)
- Is there a clear source of truth for data and reporting?
Integrations & Partners
- Are systems integrated or running in parallel?
Data governance & integrity
- Can discrepancies be traced and resolved quickly?
Exception & crisis handling
- Is business continuity considered in the design?
Change & scalability readiness
- Can your setup absorb new markets and regulations without rework?
Who This Checklist is for
This checklist is designed for pharma teams that:
- are already live with serialization
- operate across multiple sites or markets
- expect regulatory, operational, or system changes in 2026
If you’re still at “what is serialization?”, this checklist is not for you.
I appreciate the focus on helping regional banks specifically. Often, the advice out there is geared towards larger institutions and doesn’t address the specific constraints and opportunities that regional banks face. I think exploring strategies like M&A to achieve operational scale and offset regulatory compliance costs is critical for these banks1. Also, as mentioned in another article, developing or expanding niche capabilities to open up new opportunities could be a game-changer.